This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at
increased risk for thrombotic events. However, no population-based study has estimated this …

Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)
constitute theBCR-ABL1–negative myeloproliferative neoplasms and are characterized by …

Abstract Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …

Disease overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms, respectively characterized by erythrocytosis and …

Myeloproliferative neoplasms (MPN) are clonal stem cell diseases, first conceptualized in
1951 by William Dameshek, and historically included chronic myeloid leukemia (CML) …

We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in
polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled …